ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Werewolf Therapeutics Inc

Werewolf Therapeutics Inc (HOWL)

1.68
0.12
(7.69%)
Closed January 05 3:00PM
1.6985
0.0185
(1.10%)
After Hours: 6:58PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.6985
Bid
1.60
Ask
1.88
Volume
224,074
1.58 Day's Range 1.72
1.3829 52 Week Range 8.1939
Market Cap
Previous Close
1.56
Open
1.58
Last Trade Time
Financial Volume
US$ 370,019
VWAP
1.6513
Average Volume (3m)
839,543
Shares Outstanding
44,563,153
Dividend Yield
-
PE Ratio
-1.99
Earnings Per Share (EPS)
-0.84
Revenue
19.94M
Net Profit
-37.37M

About Werewolf Therapeutics Inc

Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Werewolf Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker HOWL. The last closing price for Werewolf Therapeutics was US$1.56. Over the last year, Werewolf Therapeutics shares have traded in a share price range of US$ 1.3829 to US$ 8.1939.

Werewolf Therapeutics currently has 44,563,153 shares outstanding. The market capitalization of Werewolf Therapeutics is US$69.52 million. Werewolf Therapeutics has a price to earnings ratio (PE ratio) of -1.99.

HOWL Latest News

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the β€œCompany” or β€œWerewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals...

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

– Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC Annual Meeting – – Monotherapy and combination...

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINEβ„’ Molecule for Inflammatory Diseases

WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the β€œCompany” or β€œWerewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the β€œCompany” or β€œWerewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...

Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the β€œCompany” or β€œWerewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.09856.156251.61.71.423785901.51729552CS
4-0.0915-5.111731843581.791.9451.38293382781.62706678CS
12-0.2015-10.60526315791.94.181.38298395432.63124373CS
26-0.3915-18.73205741632.094.181.38294849592.55683005CS
52-3.0115-63.93842887474.718.19391.38293653013.34064797CS
156-10.0715-85.569243840311.7712.861.38292875393.52244183CS
260-16.5115-90.672707303718.2123.991.38292544624.39172391CS

HOWL - Frequently Asked Questions (FAQ)

What is the current Werewolf Therapeutics share price?
The current share price of Werewolf Therapeutics is US$ 1.6985
How many Werewolf Therapeutics shares are in issue?
Werewolf Therapeutics has 44,563,153 shares in issue
What is the market cap of Werewolf Therapeutics?
The market capitalisation of Werewolf Therapeutics is USD 69.52M
What is the 1 year trading range for Werewolf Therapeutics share price?
Werewolf Therapeutics has traded in the range of US$ 1.3829 to US$ 8.1939 during the past year
What is the PE ratio of Werewolf Therapeutics?
The price to earnings ratio of Werewolf Therapeutics is -1.99
What is the cash to sales ratio of Werewolf Therapeutics?
The cash to sales ratio of Werewolf Therapeutics is 3.73
What is the reporting currency for Werewolf Therapeutics?
Werewolf Therapeutics reports financial results in USD
What is the latest annual turnover for Werewolf Therapeutics?
The latest annual turnover of Werewolf Therapeutics is USD 19.94M
What is the latest annual profit for Werewolf Therapeutics?
The latest annual profit of Werewolf Therapeutics is USD -37.37M
What is the registered address of Werewolf Therapeutics?
The registered address for Werewolf Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Werewolf Therapeutics website address?
The website address for Werewolf Therapeutics is werewolftx.com
Which industry sector does Werewolf Therapeutics operate in?
Werewolf Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FCUVFocus Universal Inc
US$ 0.9499
(174.93%)
260.93M
NITON2OFF Inc
US$ 2.6306
(145.85%)
358.28M
CRNCCerence Inc
US$ 19.33
(143.76%)
161.8M
KITTNauticus Robotics Inc
US$ 3.8249
(140.56%)
104.8M
ACONAclarion Inc
US$ 0.2984
(110.14%)
305.64M
HWHHWH International Inc
US$ 0.4621
(-28.80%)
7.08M
SMSTDefiance Daily Target 2x Short MSTR ETF
US$ 5.69
(-26.30%)
24.62M
RAINRain Enhancement Technologies Holdco Inc
US$ 5.59
(-23.42%)
155.16k
PTLEPTL Ltd
US$ 9.35
(-23.30%)
967.95k
NXUNXU Inc
US$ 0.725868
(-22.78%)
7.4M
NITON2OFF Inc
US$ 2.6306
(145.85%)
358.28M
TGLTreasure Global Inc
US$ 0.382
(101.58%)
337.5M
ACONAclarion Inc
US$ 0.2984
(110.14%)
305.64M
FCUVFocus Universal Inc
US$ 0.9499
(174.93%)
260.93M
NVDANVIDIA Corporation
US$ 144.47
(4.45%)
230.01M

HOWL Discussion

View Posts
tw0122 tw0122 2 months ago
Halloween is here again give it another howl. Flip time coming $4.45
πŸ‘οΈ0
tw0122 tw0122 2 months ago
$3.65 + 30% HOWLing a little some.. Title: INDUKINE™ Molecules Delivering Various Cytokines Utilize Unique Mechanisms of Action to Drive Anti-Tumor Efficacy in Murine Syngeneic Tumor Models
Abstract Number: 955
Session Date and Time: Friday, Nov. 8, 2024; 9 a.m.–8:30 p.m.
Location: George R. Brown Convention Center - Exhibit Halls A B

Title: The tumor-activated IL-12 prodrug WTX-330 expanded/activated tumor infiltrating lymphocytes and caused tumor regression in patients with refractory solid tumors: Interim data from an ongoing Ph1 study
Abstract Number: 672
Session Date and Time: Saturday, Nov. 9, 2024; 9 a.m.–8:30 p.m.
Location: George R. Brown Convention Center - Exhibit Halls A B

About Werewolf Therapeutics
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Werewolf leverages its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. The Company’s INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Werewolf’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 as a single agent in multiple tumor types and Non-Hodgkin Lymphoma. To learn more visit www.werewolftx.com.

WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.

πŸ‘οΈ0
Monksdream Monksdream 4 months ago
HOWL under $3
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
HOWL under $3
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
HOWL under $10
πŸ‘οΈ0
Monksdream Monksdream 12 months ago
HOWL new 52 week high
πŸ‘οΈ0
Pt3 Pt3 1 year ago
Yea your gap and trapped make me buy caud instead of this
πŸ‘οΈ0
TheFinalCD TheFinalCD 1 year ago
HOWL todays algo patented Gap & Trap on Phase #1 news
πŸ‘οΈ0
TheFinalCD TheFinalCD 1 year ago
https://twitter.com/Ainvest_Wire/status/1720407693737840751
πŸ‘οΈ0
TheFinalCD TheFinalCD 1 year ago
$howl flying https://finviz.com/quote.ashx?t=HOWL&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/HOWL
πŸ‘οΈ0
tw0122 tw0122 1 year ago
$3 + otw Halloween is here give it a HOWL
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
https://stockcharts.com/h-sc/ui?s=howl&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
https://stockcharts.com/h-sc/ui?s=howl&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
dip
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
dip
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
watching
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
soon
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
insert dd
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
can be big
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
wow
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
wow
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
hold
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
slow
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
slow
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
agreed
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
like thiks
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
off radar
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
catchy name
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
catchy name
πŸ‘οΈ0
surf1944 surf1944 2 years ago
https://stockcharts.com/h-sc/ui?s=howl&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/howl/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/howl/opinion
πŸ‘οΈ0
Mr. Zen Mr. Zen 2 years ago
Watch list addition, this has the potential to run, just waiting for all the pieces of the puzzle to come together.

β€œThese promising preclinical data add to a growing body of evidence demonstrating the potential of WTX-330 to drive targeted anti-tumor immune responses selectively in the tumor microenvironment (TME),” said Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer of Werewolf Therapeutics. β€œThis morning, in our Third Quarter 2022 release, we announced that the FDA has granted clearance of the investigational new drug (IND) application for WTX-330. We are excited to advance WTX-330 into the clinic and to continue developing a pipeline of novel proinflammatory cytokine therapies that have the potential to change the lives of cancer patients.”
πŸ‘οΈ0
makinezmoney makinezmoney 2 years ago
$HOWL: Hey thanks....... now 3.20.

Only getting better right ??


Enjoy those profits.





GO $HOWL
πŸ‘οΈ0
Makk1 Makk1 2 years ago
Good call here, looking very good
πŸ‘οΈ0
makinezmoney makinezmoney 2 years ago
$HOWL: Looks like its turning...... now 2.25

Let see if volume pushes it up.


The setup is nice


GO $HOWL
πŸ‘οΈ0
bobbo5 bobbo5 2 years ago
I agree and it looks like share price has been moving up this past week
πŸ‘οΈ0
dia76ca dia76ca 2 years ago
Very interesting company. I like it's chances.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock